Last reviewed · How we verify

Discontinuation of imipenem-cilastatin or meropenem

Amsterdam UMC, location VUmc · FDA-approved active Small molecule Quality 2/100

Discontinuation of imipenem-cilastatin or meropenem is a Small molecule drug developed by Amsterdam UMC, location VUmc. It is currently FDA-approved. Also known as: tienam (imipenem-cilastatin).

At a glance

Generic nameDiscontinuation of imipenem-cilastatin or meropenem
Also known astienam (imipenem-cilastatin)
SponsorAmsterdam UMC, location VUmc
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Discontinuation of imipenem-cilastatin or meropenem

What is Discontinuation of imipenem-cilastatin or meropenem?

Discontinuation of imipenem-cilastatin or meropenem is a Small molecule drug developed by Amsterdam UMC, location VUmc.

Who makes Discontinuation of imipenem-cilastatin or meropenem?

Discontinuation of imipenem-cilastatin or meropenem is developed and marketed by Amsterdam UMC, location VUmc (see full Amsterdam UMC, location VUmc pipeline at /company/amsterdam-umc-location-vumc).

Is Discontinuation of imipenem-cilastatin or meropenem also known as anything else?

Discontinuation of imipenem-cilastatin or meropenem is also known as tienam (imipenem-cilastatin).

What development phase is Discontinuation of imipenem-cilastatin or meropenem in?

Discontinuation of imipenem-cilastatin or meropenem is FDA-approved (marketed).

Related